OGEN Spikes 200% In 2 Days, TRPX On A High, INO Turning Heads

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Oragenics Inc. (OGEN)

Gained 123.12% to close Tuesday's (Oct.2) trading at $3.57.

News: The Company made a presentation at the Ladenburg Thalmann 2018 Healthcare Conference.

Clinical Trial & Near-term Catalyst:

In August of this year, the Company resumed its phase II clinical trial of AG013, a live biotherapeutic product for the potential treatment of oral mucositis following a positive review by an independent Data Safety Monitoring Board (DSMB).

The study is expected to be completed next year.

2. SELLAS Life Sciences Group Inc. (SLS)

Gained 39.83% to close Tuesday's trading at $1.65.

News: Data from a phase IIb trial of the Company's investigational NeuVax in combination with Genentech's Herceptin for the treatment of women with triple-negative breast cancer will be presented in a poster presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 9.

The interim data reported from the NeuVax + Herceptin combination trial, reported in April of this year, demonstrated clinically meaningful activity in favor of investigational NeuVax + Herceptin arm, and clinically and statistically significant efficacy in triple negative breast cancer (TNBC) cohort.

3. Therapix Biosciences Ltd. (TRPX)

Therapix Biosciences is a specialty clinical-stage pharmaceutical company developing unique cannabinoid technologies for treatment of central nervous system disorders.

Gained 22.10% to close Tuesday's trading at $5.58.

News: No news

Clinical Trials & Near-term Catalysts:

-- The first patient in a phase IIb, placebo-controlled 12-week clinical trial for THX-110 in Tourette syndrome, which will be conducted in Germany, is expected to be enrolled by the end of the third quarter. Top line results are expected in the first half of 2020. -- A phase IIa sponsor-initiated trial with THX-110 in Obstructive Sleep Apnea is underway, with top line results expected in the first half of 2019.

The other ongoing studies are a phase IIa investigator-initiated trial with THX-110 for the treatment of chronic pain, a pre-clinical study evaluating THX-130 in a rodent model for cognitive impairment related to traumatic brain injury; pre-clinical study of THX-150 for the treatment of infectious diseases, and a pre-clinical study of THX-160 for the treatment of pain.

4. Orgenesis Inc. (ORGS)

Gained 20.56% to close Tuesday's trading at $6.45.

News: Kangstem Biotech Co., Ltd., a biotechnology company specializing in developing cell therapies using mesenchymal stem cells derived from human umbilical cord blood, has selected Orgenesis' subsidiary, Masthercell Global Inc., as its contract manufacturing partner for the European clinical trials of Furestem-AD, a cell therapy designed to treat atopic dermatitis.

Furestem-AD is advancing into late phase trials in Korea.

Recent event:

-- On July 17, the Company reported financial results for the fiscal second quarter ended May 31, 2018.

Net loss for the three months ended May 31, 2018 was $2.6 million or $0.20 per share compared to $2.5 million or $0.26 per share for the three months ended May 31, 2017. Revenue for the recent fiscal second quarter increased 73% to $4.0 million from $2.3 million for the corresponding quarter last year.

5. Antares Pharma Inc. (ATRS)

Gained 15.64% to close Tuesday's trading at $3.77.

News: No news

Recent event:

-- On October 1, the FDA approved the Company's Xyosted Injection for testosterone replacement therapy in adult males.

The once-weekly XYOSTED has been approved in three dosage strengths, 50 mg, 75 mg and 100 mg, and is expected to be made available to patients before the end of this year.

6. Inovio Pharmaceuticals Inc. (INO)

Gained 14.21% to close Tuesday's trading at $6.11.

News: A paper published in a major cancer journal detailed results of a patient with head and neck cancer treated with MEDI0457 achieved a sustained complete response (full remission) on treatment with a subsequent PD-1 checkpoint inhibitor.

In the Inovio-sponsored study of 22 patients with head and neck squamous cell carcinoma, the Company reported 91% (20/22) showed T cell activity in the blood or tissue.

MEDI0457, formerly called INO-3112, was in 2015 licensed to MedImmune, the global biologics research and development arm of AstraZeneca.